• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基因治疗重回舞台中央。

Gene therapy returns to centre stage.

机构信息

San Raffaele Telethon Institute for Gene Therapy (TIGET), San Raffaele Scientific Institute, 20132 Milan, Italy.

Vita Salute San Raffaele University, 20132 Milan, Italy.

出版信息

Nature. 2015 Oct 15;526(7573):351-60. doi: 10.1038/nature15818.

DOI:10.1038/nature15818
PMID:26469046
Abstract

Recent clinical trials of gene therapy have shown remarkable therapeutic benefits and an excellent safety record. They provide evidence for the long-sought promise of gene therapy to deliver 'cures' for some otherwise terminal or severely disabling conditions. Behind these advances lie improved vector designs that enable the safe delivery of therapeutic genes to specific cells. Technologies for editing genes and correcting inherited mutations, the engagement of stem cells to regenerate tissues and the effective exploitation of powerful immune responses to fight cancer are also contributing to the revitalization of gene therapy.

摘要

最近的基因治疗临床试验显示出显著的治疗效果和极好的安全性记录。它们为基因治疗长期以来的承诺提供了证据,即可以为某些原本致命或严重致残的疾病提供“治愈”方法。这些进展背后是改进的载体设计,能够安全地将治疗基因递送到特定的细胞。编辑基因和纠正遗传突变的技术、利用干细胞来再生组织以及有效地利用强大的免疫反应来对抗癌症的技术也为基因治疗的复兴做出了贡献。

相似文献

1
Gene therapy returns to centre stage.基因治疗重回舞台中央。
Nature. 2015 Oct 15;526(7573):351-60. doi: 10.1038/nature15818.
2
Toward Clinical Translation of New Gene Targeting Technologies for Correcting Inherited Mutations and Empowering Adoptive Immunotherapy of Cancer (SUPERSIST).迈向新型基因靶向技术的临床转化,以纠正遗传性突变并增强癌症过继性免疫疗法(SUPERSIST)。
Hum Gene Ther Clin Dev. 2015 Jun;26(2):95-7. doi: 10.1089/humc.2015.2529.
3
IND-Enabling Studies for a Clinical Trial to Genetically Program a Persistent Cancer-Targeted Immune System.为一项临床试验进行基因编程以建立持久的癌症靶向免疫系统的 IND 研究。
Clin Cancer Res. 2019 Feb 1;25(3):1000-1011. doi: 10.1158/1078-0432.CCR-18-0963. Epub 2018 Nov 8.
4
Contributions of gene marking to cell and gene therapies.基因标记对细胞和基因治疗的贡献。
Hum Gene Ther. 2011 Jun;22(6):659-68. doi: 10.1089/hum.2010.237. Epub 2011 May 5.
5
Retroviral Vectors for Cancer Gene Therapy.用于癌症基因治疗的逆转录病毒载体
Recent Results Cancer Res. 2016;209:17-35. doi: 10.1007/978-3-319-42934-2_2.
6
Historical Perspective on the Current Renaissance for Hematopoietic Stem Cell Gene Therapy.造血干细胞基因治疗当前复兴的历史视角
Hematol Oncol Clin North Am. 2017 Oct;31(5):721-735. doi: 10.1016/j.hoc.2017.06.006.
7
Hematopoietic Stem Cell Approaches to Cancer.癌症的造血干细胞治疗方法。
Hematol Oncol Clin North Am. 2017 Oct;31(5):897-912. doi: 10.1016/j.hoc.2017.06.012.
8
Humanized mice are precious tools for evaluation of hematopoietic gene therapies and preclinical modeling to move towards a clinical trial.人源化小鼠是评估造血基因治疗和临床前建模以推进临床试验的宝贵工具。
Biochem Pharmacol. 2020 Apr;174:113711. doi: 10.1016/j.bcp.2019.113711. Epub 2019 Nov 11.
9
A Cetuximab-Mediated Suicide System in Chimeric Antigen Receptor-Modified Hematopoietic Stem Cells for Cancer Therapy.嵌合抗原受体修饰造血干细胞中的西妥昔单抗介导自杀系统用于癌症治疗。
Hum Gene Ther. 2019 Apr;30(4):413-428. doi: 10.1089/hum.2018.180.
10
Editing of Endogenous Genes in Cellular Immunotherapies.内源性基因编辑在细胞免疫疗法中的应用
Curr Hematol Malig Rep. 2020 Aug;15(4):235-240. doi: 10.1007/s11899-020-00587-0.

引用本文的文献

1
In vivo CAR-T cell therapy: New breakthroughs for cell-based tumor immunotherapy.体内CAR-T细胞疗法:基于细胞的肿瘤免疫疗法的新突破。
Hum Vaccin Immunother. 2025 Dec;21(1):2558403. doi: 10.1080/21645515.2025.2558403. Epub 2025 Sep 11.
2
Advancing gene editing therapeutics: Clinical trials and innovative delivery systems across diverse diseases.推进基因编辑疗法:针对多种疾病的临床试验和创新递送系统
Mol Ther Nucleic Acids. 2025 Aug 5;36(3):102666. doi: 10.1016/j.omtn.2025.102666. eCollection 2025 Sep 9.
3
CAR T-cell therapy in autoimmune diseases: a promising frontier on the horizon.

本文引用的文献

1
Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas.人类肝细胞癌中反复出现的 AAV2 相关插入性突变。
Nat Genet. 2015 Oct;47(10):1187-93. doi: 10.1038/ng.3389. Epub 2015 Aug 24.
2
Gene therapy outpaces haplo for SCID-X1.基因治疗在 X-连锁重症联合免疫缺陷病(SCID-X1)的治疗中进展迅速。
Blood. 2015 Jun 4;125(23):3521-2. doi: 10.1182/blood-2015-04-641720.
3
Improving the safety of cell therapy with the TK-suicide gene.利用胸苷激酶自杀基因提高细胞治疗的安全性。
自身免疫性疾病中的嵌合抗原受体T细胞疗法:一个充满前景的前沿领域。
Front Immunol. 2025 Aug 12;16:1613878. doi: 10.3389/fimmu.2025.1613878. eCollection 2025.
4
Modeling integration site data for safety assessment with MELISSA.使用MELISSA对整合位点数据进行安全性评估建模。
Nat Commun. 2025 Aug 23;16(1):7868. doi: 10.1038/s41467-025-63017-w.
5
Advancements in CRISPR-Cas Systems for Genome Editing towards Eradication of Human Microbial Pathogens.用于基因组编辑以根除人类微生物病原体的CRISPR-Cas系统的进展
Mol Biotechnol. 2025 Aug 20. doi: 10.1007/s12033-025-01482-w.
6
Application of Gene Therapy to Oral Diseases.基因治疗在口腔疾病中的应用。
Pharmaceutics. 2025 Jun 30;17(7):859. doi: 10.3390/pharmaceutics17070859.
7
Sweet and sticky: increased cell adhesion through click-mediated functionalization of regenerative liver progenitor cells.甜蜜且黏附:通过点击介导的再生肝祖细胞功能化增强细胞黏附
Commun Biol. 2025 Jul 10;8(1):1023. doi: 10.1038/s42003-025-08408-x.
8
High-throughput multiplexed gene and cell doping analysis through CRISPR-Cas12a system integrated with blood direct PCR.通过与血液直接PCR整合的CRISPR-Cas12a系统进行高通量多重基因和细胞掺杂分析。
Sci Adv. 2025 Jul 11;11(28):eadv7234. doi: 10.1126/sciadv.adv7234. Epub 2025 Jul 9.
9
Unlocking the potential: advancements and applications of gene therapy in severe disorders.释放潜能:基因疗法在严重疾病中的进展与应用
Ann Med. 2025 Dec;57(1):2516697. doi: 10.1080/07853890.2025.2516697. Epub 2025 Jun 17.
10
Gene therapy of rare diseases as a milestone in medicine - overview of the field and report on initial experiences in Slovenia.罕见病的基因治疗作为医学上的一个里程碑——该领域概述及斯洛文尼亚的初步经验报告
Orphanet J Rare Dis. 2025 Jun 5;20(1):279. doi: 10.1186/s13023-025-03828-8.
Front Pharmacol. 2015 May 5;6:95. doi: 10.3389/fphar.2015.00095. eCollection 2015.
4
CRISPR germline engineering--the community speaks.CRISPR种系工程——学界发声。
Nat Biotechnol. 2015 May;33(5):478-86. doi: 10.1038/nbt.3227.
5
Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults.用编码TRAP的黑猩猩腺病毒和改良痘苗病毒安卡拉进行初免-加强免疫接种,可为肯尼亚成年人提供针对恶性疟原虫感染的部分保护。
Sci Transl Med. 2015 May 6;7(286):286re5. doi: 10.1126/scitranslmed.aaa2373.
6
Clinical Scale Zinc Finger Nuclease-mediated Gene Editing of PD-1 in Tumor Infiltrating Lymphocytes for the Treatment of Metastatic Melanoma.临床规模锌指核酸酶介导的肿瘤浸润淋巴细胞中PD-1基因编辑用于治疗转移性黑色素瘤
Mol Ther. 2015 Aug;23(8):1380-1390. doi: 10.1038/mt.2015.71. Epub 2015 May 5.
7
Long-term effect of gene therapy on Leber's congenital amaurosis.基因治疗对莱伯先天性黑蒙的长期影响。
N Engl J Med. 2015 May 14;372(20):1887-97. doi: 10.1056/NEJMoa1414221. Epub 2015 May 4.
8
Long-term effects of retinal gene therapy in childhood blindness.视网膜基因治疗对儿童失明的长期影响。
N Engl J Med. 2015 May 14;372(20):1954-5. doi: 10.1056/NEJMe1503419. Epub 2015 May 4.
9
Improvement and decline in vision with gene therapy in childhood blindness.儿童失明基因治疗后的视力改善与下降
N Engl J Med. 2015 May 14;372(20):1920-6. doi: 10.1056/NEJMoa1412965. Epub 2015 May 3.
10
Outcomes following gene therapy in patients with severe Wiskott-Aldrich syndrome.重症威斯科特-奥尔德里奇综合征患者基因治疗后的结果。
JAMA. 2015 Apr 21;313(15):1550-63. doi: 10.1001/jama.2015.3253.